Skip to main content

Table 3 Response assessment to treatment

From: Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study

Response

Number of patients

Complete response

3 (15.8%)

Partial response

9 (47.3%)

Stabilisation

4 (21.1%)

Progression

3 (15.8%)

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us